Multicentrická štúdia demonštruje minimálne invazívny test sušených krvných škvŕn z kapilárnej krvi na detekciu patológie Alzheimerovej choroby. The test measures biomarkers such as p-tau217, GFAP and NfL, which identify changes in the brain with high accuracy. The level of p-tau217 in finger blood samples identifies Alzheimer's changes in the spinal cord with 86 percent accuracy. Biomarkers show high agreement with the results of standard blood tests and measurements in the cerebral spinal cord. Participants drew their own blood without the help of researchers, allowing for remote testing. This approach is scalable for research in resource-limited populations where refrigerated transport is not required. The test has potential for large studies and groups at higher risk, such as people with Down syndrome. Additional validation is needed for clinical use.